

Appendix

Supplementary information	2
Search strategies in the literature review	2
Supplementary Table	4
Table S1. Inputs used to estimate the hours per day of informal care by events	4
Table S2. Hourly wage used to proxy of the market value of informal care time, rate exchange and GDP by country, 2020 USD	6
Table S3. Total number of cases per health events and country in a year	6
Table S4. Medical direct costs per health event and country, million 2020	7

Supplementary information

Search strategies in the literature review

PUBMED

Cardiovascular diseases

(Caregivers[Mesh] OR Care Giver*[tiab] OR Caregiver*[tiab] OR Informal Care*[tiab]) AND (Cardiovascular Diseases[Mesh] OR Cardiovascular[tiab] OR Myocardial Ischemia[Mesh] OR Acute Coronar*[tiab] OR Coronary Syndrom*[tiab] OR STEMI[tiab] OR non-STEMI[tiab] OR Myocardial isch*[tiab] OR Stroke*[tiab]) AND (Time Management[Mesh] OR Time and Motion Studies[Mesh] OR Use-of-Time[tiab] OR time[tiab] OR hours[tiab] OR Economic burden[tiab] OR burden[tiab] OR Disease Cost*[tiab] OR Indirect Cost*[tiab] OR cost-of-illness[tiab]) AND (Systematic Review[sb] OR Systematic Review[tiab] OR Meta-Analysis[pt] OR Meta-Analys*[tiab] OR "Cochrane Database Syst Rev"[ta] OR Metaanalysis[tiab] OR Metanalysis[tiab] OR Overview[ti] OR (Review[ti] AND Literature[ti]) OR (MEDLINE[tiab] AND Cochrane[tiab]))

Cancers

(Caregivers[Mesh] OR Care Giver*[tiab] OR Caregiver*[tiab] OR Informal Care*[tiab]) AND (Neoplasms[Mesh] OR Cancer[tiab]) AND (Time Management[Mesh] OR Time and Motion Studies[Mesh] OR Use-of-Time[tiab] OR time[tiab] OR hours[tiab] OR Economic burden[tiab] OR burden[tiab] OR Disease Cost*[tiab] OR Indirect Cost*[tiab] OR cost-of-illness[tiab]) AND (Systematic Review[sb] OR Systematic Review[tiab] OR Meta-Analysis[pt] OR Meta-Analys*[tiab] OR "Cochrane Database Syst Rev"[ta] OR Metaanalysis[tiab] OR Metanalysis[tiab] OR Overview[ti] OR (Review[ti] AND Literature[ti]) OR (MEDLINE[tiab] AND Cochrane[tiab]))

Pulmonary diseases.

(Caregivers[Mesh] OR Care Giver*[tiab] OR Caregiver*[tiab] OR Informal Care*[tiab]) AND (Pulmonary Disease, Chronic Obstructive[Mesh] OR COPD[tiab] OR Chronic Obstructive[tiab] OR Obstructive Airway[tiab] OR Pulmonary Disease*[tiab]) AND (Time Management[Mesh] OR Time and Motion Studies[Mesh] OR Use-of-Time[tiab] OR time[tiab] OR hours[tiab] OR Economic burden[tiab] OR burden[tiab] OR Disease Cost*[tiab] OR Indirect Cost*[tiab] OR cost-of-illness[tiab]) AND (Systematic Review[sb] OR Systematic Review[tiab] OR Meta-Analysis[pt] OR Meta-Analys*[tiab] OR "Cochrane Database Syst Rev"[ta] OR Metaanalysis[tiab] OR Metanalysis[tiab] OR Overview[ti] OR (Review[ti] AND Literature[ti]) OR (MEDLINE[tiab] AND Cochrane[tiab]))

LILACS

(MH Caregivers OR Caregiver\$ OR Cuidador\$ OR Carer) AND (Tiempo OR Tempo OR Time) AND (MH Neoplasms OR MH Pneumonia OR MH Cardiovascular Diseases OR Cardiovascular OR Cancer OR Coronar\$ OR EPOC OR stroke OR ACV OR Cerebrovascular OR Chronic obstructive pulmonary disease)

Supplementary Table

Table S1. Inputs used to estimate the hours per day of informal care by events

Events	Utility	Source	Care days per year[15]	Use rate[15]
Acute Myocardial Infarction (first year)	0.803	Smith [1]	30	65%
Coronary event no AMI (first year)	0.803	Smith [1]	30	65%
Coronary event (year 2+)	0.850	Wijeysundera [2]	365	5%
Stroke (first year)	0.620	Yeoh [3]	60	33%
Stroke (year 2+)	0.780	Yeoh [3]	365	17%
Mild COPD	0.935	Mölken [4]	365	0%
Moderate COPD	0.776	Mölken[4]	365	60%
Severe COPD	0.689	Mölken [4]	365	80%
Pneumonia	0.994	Pepper [5]	30	65%
Lung cancer	0.660	Chouaid [6]	365	100%
Mouth cancer	0.745	Nie [7]	365	100%
Esophageal cancer	0.630	Graham [8]	365	100%
Stomach cancer	0.550	Dan [9]	365	100%
Pancreas cancer	0.550	Gordois [10]	365	100%
Kidney cancer	0.780	Pickard [11]	365	100%
Laryngeal cancer	0.760	Pickard [11]	365	100%
Leukemia	0.820	Leunis [12]	365	100%
Bladder cancer	0.678	Hevér [13]	365	100%
Neck cancer	0.758	Endarti [14]	365	100%

Note:

Equation resulting from the econometric estimation for missing data of informal care hours of time: $y = -13.32 \cdot x + 12.325$

References:

1 Smith DW, Davies EW, Wissinger E, Huelin R, Matza LS, Chung K. A systematic literature review of cardiovascular event utilities. Vol. 13, Expert Review of Pharmacoeconomics and Outcomes Research. 2013.

2 Wijeysundera HC, Farshchi-Zarabi S, Witteman W, Bennell MC. Conversion of the Seattle Angina questionnaire into EQ-5D utilities for ischemic heart disease: A systematic review and catalog of the literature. Clin Outcomes Res. 2014;6(1).

- 3 Yeoh YS, Koh GCH, Tan CS, Tu TM, Singh R, Chang HM, et al. Health-related quality of life loss associated with first-time stroke. *PLoS One*. 2019;14(1).
- 4 Mölken MR Van, Lee TA. Economic modeling in chronic obstructive pulmonary disease. In: *Proceedings of the American Thoracic Society*. 2006.
- 5 Pepper PV, Owens DK. Cost-effectiveness of the pneumococcal vaccine in healthy younger adults. *Med Decis Mak*. 2002;22(5 SUPPL.).
- 6 Chouaid C, Agulnik J, Goker E, Herder GJM, Lester JF, Vansteenkiste J, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: A prospective cross-sectional patient survey in a real-world setting. *J Thorac Oncol*. 2013;8(8).
- 7 Nie M, Liu C, Pan YC, Jiang CX, Li BR, Yu XJ, et al. Development and evaluation of oral Cancer quality-of-life questionnaire (QOL-OC). *BMC Cancer*. 2018;18(1).
- 8 Graham AJ, Shrive FM, Ghali WA, Manns BJ, Grondin SC, Finley RJ, et al. Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis. *Ann Thorac Surg*. 2007;83(4).
- 9 Dan YY, So JBY, Yeoh KG. Endoscopic Screening for Gastric Cancer. *Clin Gastroenterol Hepatol*. 2006;4(6).
- 10 Gordoia A, Scuffham P, Warren E, Ward S. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. *Br J Cancer*. 2003;89(4).
- 11 Pickard AS, Jiang R, Lin HW, Rosenbloom S, Cella D. Using Patient-reported Outcomes to Compare Relative Burden of Cancer: EQ-5D and Functional Assessment of Cancer Therapy-General in Eleven Types of Cancer. *Clin Ther*. 2016;38(4).
- 12 Leunis A, Redekop WK, Uyl-de Groot CA, Löwenberg B. Impaired health-related quality of life in acute myeloid leukemia survivors: A single-center study. *Eur J Haematol*. 2014;93(3).
- 13 Hevér N V., Péntek M, Balló A, Gulácsi L, Baji P, Brodszky V, et al. Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. *Pathol Oncol Res*. 2015;21(3).
- 14 Endarti D, Riewpaiboon A, Thavorncharoensap M, Praditsitthikorn N, Hutubessy R, Kristina SA. Evaluation of health-related quality of life among patients with cervical cancer in Indonesia. *Asian Pacific J Cancer Prev*. 2015;16(8).
- 15 Own elaboration based Interviews with health professionals

Table S2. Hourly wage used to proxy of the market value of informal care time, rate exchange and GDP by country, 2020 USD

Exchange and GDP by country, 2020 USD					
Countries	Wage per hour			Rate exchange (LC/USD)	GDP (in million USD)
	Mean	IC 95%			
		IL	UL		
Argentina	2.32	1.24	2.85	70.63	\$421237.14
Brazil	2.59	1.10	2.76	5.38	\$1273118.68
Chile	4.12	2.38	4.50	792.17	\$240312.29
Colombia	1.34	1.25	2.24	3693.28	\$270842.50
Costa Rica	2.91	2.81	3.62	584.94	\$59698.45
Ecuador	2.97	2.51	3.39	1	\$100667.53
Mexico	1.05	0.18	1.49	21.5	\$1051525.22
Peru	2.39	1.39	2.15	3.49	\$207161.12

Source: Own elaboration based national surveys.

Note: LC: Local currency

Table S3. Total number of cases per health events and country in a year

Events	Argentina	Brazil	Chile	Colombia	Costa Rica	Ecuador	Peru	Mexico
Acute Myocardial Infarction (first year)	107539	877966	42998	181679	7627	59770	20716	387114
Coronary event no AMI (first year)	169148	1033378	67972	156007	33503	16085	12902	250370
Coronary event (year 2+)	2301017	17315235	1024722	1900212	334026	638821	318016	4660273
Stroke (first year)	94631	345054	74802	183357	5683	37924	53016	261026
Stroke (year 2+)	664481	2680302	522322	1432941	30919	259314	428598	1887680
Pneumonia	183185	792625	29072	57286	7178	34239	110662	265385
Mild COPD	1719609	7143987	966812	1569348	132836	400352	1203821	3305023
Moderate COPD	373735	1522848	215242	346907	27934	84071	275575	707501
Severe COPD	72284	288830	42455	68290	5262	15780	57045	135897
Lung cancer	34329	90045	12685	15910	1443	2859	9085	24693
Mouth cancer	9689	62758	2644	6629	713	1166	4341	11362
Esophageal cancer	9460	42560	3491	3584	371	744	1675	4798
Stomach cancer	16301	76348	19268	28058	3531	8540	21363	28943
Pancreas cancer	21101	53060	7804	10399	1185	2164	6571	19681
Kidney cancer	18041	29995	8375	5101	710	1425	5519	16665
Laryngeal cancer	6395	34078	1351	3311	453	564	1041	5793
Leukemia	10461	35677	4993	9160	974	2729	6334	15315
Bladder cancer	15049	45839	5893	5941	831	1291	3309	7841
Neck cancer	15193	51752	5770	13069	1128	4898	13883	25979
Total	5841647	32522338	3058670	5997190	596306	1572736	2553472	12021339

Source: Extracted and updated to Pichon-Riviere et al (2020)

Table S4. Medical direct costs per health event and country, million 2020 USD

Events	Argentina	Brazil	Chile	Colombia	Costa Rica	Ecuador	Mexico	Peru
Coronary events	4059	10195	1877	2817	693	1286	8232	493
Stroke	405	2720	1139	794	89	430	2223	655
COPD	744	6090	628	489	86	241	2775	567
Pneumonia	93	215	7	41	13	16	335	21
Cancers	2375	2753	1213	684	239	322	1493	855
Total	7676	21973	4863	4824	1120	2295	15058	2590

Source: Extracted and updated to Pichon-Riviere et al (2020)